KeyBanc raised the firm’s price target on Solventum (SOLV) to $99 from $97 and keeps an Overweight rating on the shares following quarterly results. The firm believes investors will view the company’s Q4 results and 2026 outlook as mostly positive, given steady progress toward 2028 targets despite some continued near-term moving pieces.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SOLV:
- Solventum sees 2026 adjusted EPS $6.40-$6.60, consensus $6.34
- Solventum reports Q4 adjusted EPS $1.57, consensus $1.50
- Trian boosts stakes in GE Aerospace and GE Healthcare, cuts Invesco stake
- Balanced View on Solventum: Differentiated Healthcare IT AI Offsets Early-Stage Turnaround Risk, Supporting a Hold Rating
- Solventum upgraded to Overweight from Sector Weight at KeyBanc